Welcome to our dedicated page for MNNDF news (Ticker: MNNDF), a resource for investors and traders seeking the latest updates and insights on MNNDF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MNNDF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MNNDF's position in the market.
Nurosene Health Inc. will officially change its corporate name to NetraMark Holdings Inc. and its trading symbol to AIAI effective February 1, 2023, while continuing to trade on the Canadian Securities Exchange (CSE). This name change reflects the company’s strategic shift towards developing Artificial Intelligence (AI) and Machine Learning (ML) solutions for the pharmaceutical industry. With the launch of its NetraAI technology, the company aims to tackle challenges in clinical trials by efficiently utilizing small datasets. CEO George Achilleos and President Josh Spiegel highlight the potential impact of AI in enhancing drug efficacy and safety.
Nurosene Health Inc. (CSE: MEND, OTC: MNNDF) has announced a strategic advisory relationship with RARE-X, a collaborative platform for rare disease data. This partnership enables NetraMark, Nurosene's subsidiary, to access valuable rare disease datasets to enhance its AI capabilities. Dr. Joseph Geraci from NetraMark will join the RARE-X Advisory Board for the Xcelerate RARE data challenge, aiming to leverage NetraAI technology for generating therapeutic hypotheses for rare diseases. The collaboration highlights Nurosene's commitment to advancing treatments for rare disorders and improving patient outcomes in the pharmaceutical industry.
Nurosene Health Inc. (CSE: MEND, OTC: MNNDF) announced a strategic shift to enhance its AI/ML offerings for the pharmaceutical industry via its subsidiary, NetraMark. The focus is on improving clinical trial success rates, which currently stand below 12% for Phase 1 trials. The company aims to leverage its NetraAI technology to tackle the low success rates in clinical trials, with over $40B spent on these processes annually. Nurosene is assembling a skilled executive team to accelerate commercialization efforts and capitalize on growing market opportunities.
Nurosene Health Inc. has announced the successful closing of a non-brokered private placement, issuing 2,910,000 units at $0.25 each, resulting in gross proceeds of $727,500. Each unit consists of one common share and one warrant, allowing the acquisition of an additional share at $0.40 for 36 months. Insiders purchased 840,000 units for $210,000, exempting the transaction from certain regulations. The funds will be directed towards working capital, and a finder's fee of $34,475 was paid. Following this, there are now 45,431,102 common shares outstanding.
Nurosene Health is partnering with Cyclica to enhance drug discovery for neurodegenerative diseases valued at nearly USD $40 Billion. The agreement, signed on February 7, 2022, leverages Nurosene's AI tool, NetraHealthAtlas, to identify drug targets, aiming to reduce costs and time in drug development. This collaboration aims to produce innovative treatments for conditions like Alzheimer’s and Parkinson’s. The partnership also involves milestone payments and royalties related to the drug development process.
FAQ
What is the market cap of MNNDF (MNNDF)?
